A global research team led by The University of Notre Dame Australia School of Medicine’s Professor Merrilee Needham, in collaboration with the Perron Institute, Fiona Stanley Hospital and Murdoch University was awarded $1.8 million in funding for the trial of a re-purposed drug (Sirolimus) in the treatment of the rare disease Inclusion Body Myositis (IBM).
Consumer and community members have been at the forefront of this research and contributed to the successful grant application. In total $3.5 million was awarded by the Australian Government investment into 17 cutting-edge research projects.
“This study will be led from Australia to allow access for as many Australian IBM patients as possible, and we are so delighted to offer our patients a trial of a potential treatment, and more importantly, hope for their future”, Professor Needham said.
Read the media release from the University of Notre Dame Australia